The Design and Synthesis of a Potential DEN2 Anti-Viral Agent
소속 :
연사 : Prof. Noorsaadah Rahman(University Malaya)
일시 : 2012-10-29 17:00 ~
장소 : 500동 목암홀
일 시 : 2012년 11월 29일, 5:00 PM
장 소 : 500동 목암홀
-Abstract-
Dengue is a serious disease that is endemic in over 100 countries, with more than 2.5 billion people at risk for epidemic transmission. About 100 million cases of Dengue Fever (DF) and 500 000 cases of Dengue Haemorrhagic Fever (DHF) have been reported globally and this figure has been on the rise in the recent years.
The search of an anti-viral for dengue virus infection has been focused on the different phases of the viral lifecycle (virus attachment, viral entry, trafficking, translation or replication). Despite its morbidity and mortality, only few antiviral therapies have been tested and little is known about the effects and mechanisms of the anti-viral agents. To date there is no vaccine or anti-viral drug available to treat dengue virus infection.
Natural products have also been a source of lead compounds for drugs for decades. Newman, Cragg and Snader reported in 2003 that during the period from1981 to 2002, 61% of the 877 new small molecules introduced as drugs worldwide can be traced to or were inspired by natural products. In certain areas, natural products have been more successful than others. For example, it has been reported that 78% of antibacterials and 74% of anticancer compounds are natural products or have been derived from, or inspired by, a natural product.
In our effort to search for a potential thereapeutic drug for dengue fever, we have used different approaches ranging from bio-assay guided screening of natural product extracts to molecular modeling for the design of a novel inhibitor for the DEN2 virus protease and synthesis of the designed compound.
Some of the results on the biological activity of natural products and compounds synthesized will be discussed. The use of these compounds as a template for molecular docking and designing of novel inhibitor for dengue virus as well as the synthesis of the designed compound is also described
장 소 : 500동 목암홀
-Abstract-
Dengue is a serious disease that is endemic in over 100 countries, with more than 2.5 billion people at risk for epidemic transmission. About 100 million cases of Dengue Fever (DF) and 500 000 cases of Dengue Haemorrhagic Fever (DHF) have been reported globally and this figure has been on the rise in the recent years.
The search of an anti-viral for dengue virus infection has been focused on the different phases of the viral lifecycle (virus attachment, viral entry, trafficking, translation or replication). Despite its morbidity and mortality, only few antiviral therapies have been tested and little is known about the effects and mechanisms of the anti-viral agents. To date there is no vaccine or anti-viral drug available to treat dengue virus infection.
Natural products have also been a source of lead compounds for drugs for decades. Newman, Cragg and Snader reported in 2003 that during the period from1981 to 2002, 61% of the 877 new small molecules introduced as drugs worldwide can be traced to or were inspired by natural products. In certain areas, natural products have been more successful than others. For example, it has been reported that 78% of antibacterials and 74% of anticancer compounds are natural products or have been derived from, or inspired by, a natural product.
In our effort to search for a potential thereapeutic drug for dengue fever, we have used different approaches ranging from bio-assay guided screening of natural product extracts to molecular modeling for the design of a novel inhibitor for the DEN2 virus protease and synthesis of the designed compound.
Some of the results on the biological activity of natural products and compounds synthesized will be discussed. The use of these compounds as a template for molecular docking and designing of novel inhibitor for dengue virus as well as the synthesis of the designed compound is also described
